UNSPSC 51111847: Erbulozole

This classification denotes a tubulin binding agent with the molecular formula C24H27N3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 78XGN2K5RX, chemically known as ethyl (+-)-cis-p-(((2-(imidazol-1-ylmethyl)-2-(p-methoxyphenyl)-1,3-dioxolan-4-yl)methyl)thio)carbanilate but generally known as erbulozole, which bears US NIH Compound Identifier 71347. The term ERBULOZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29).

As of Q4 2014, ERBULOZOLE remains the US FDA Preferred Term for this commodity. Erbulozole bears US NLM identifiers UMLS ID C0059504 and NCI Concept Code C73258. SMILES: CCOC(=O)NC1=CC=C(C=C1)SCC2CO[C@](O2)(CN3C=CN=C3)C4=CC=C(C=C4)OC..

UNSPSC 51111847 Erbulozole is a Commodity code that encompasses pharmaceutical active ingredients and finished-dose products supplied through state and local cooperative purchasing vehicles. State and local governments procure under this code primarily through multistate cooperative alliances that aggregate demand across participating jurisdictions and their healthcare, correctional, and social-service facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is a significant issuing body in this space, establishing blanket contracts with multiple manufacturers and wholesalers to supply generic pharmaceuticals and OTC products on a standing basis. These procurements typically require vendors to maintain cGMP certification and DSCSA compliance, establish relationships with authorized pharmaceutical wholesalers through chargeback systems, and provide detailed product-level data including NDC codes, SKUs, and packaging configurations. Insurance requirements—including $5 million general liability and $2 million network security and privacy coverage—are standard, and contracts include performance penalties for late reporting or missed onboarding timelines.

MMCAP's recent RFP (Solicitation S1070000015802, due March 26, 2026) illustrates the scope and scale of current activity. The cooperative is seeking manufacturers to supply generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions, with awarded vendors compensated through tiered pricing models (flat price, net price, or WAC-minus structures) and subject to a 3 percent administrative fee on all contract purchases. Award decisions are multi-award in nature, with MMCAP reserving discretion to select vendors based on therapeutic considerations, product availability, and patient safety. Evaluation emphasizes price competitiveness (75 percent of scoring) with secondary weight on pricing format compliance, EDI capability, and administrative fee agreement. Contract terms run two years for new responders with optional extensions, while incumbent amendments extend through June 30, 2028. Submissions require Google Chrome access to the ePro system and formatted Excel-to-CSV pricing and product data.